News from ambrx inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 21, 2016, 20:00 ET Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients

 Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) announced today that they initiated First-In-Human phase I clinical trial with ARX788, Ambrx's most...


Nov 16, 2015, 10:22 ET Ambrx Announces New Chief Medical Officer

 Ambrx today announced the appointment of Yong-Jiang Hei, M.D., Ph.D. as Chief Medical Officer (CMO) reporting directly to CEO, Tiecheng "Alex"...


Apr 29, 2014, 12:40 ET Ambrx and Zhejiang Hisun Pharmaceutical to Collaborate on the Development and Commercialization of Bispecifics for Cancer

 Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code: 600267) today announced a collaboration for the development and...


Feb 24, 2014, 09:00 ET Sheila Gujrathi, M.D., Joins Ambrx Board of Directors

 Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer...


Feb 05, 2014, 09:00 ET Ambrx Appoints Barry Greene to Board of Directors

 Ambrx Inc. today announced the appointment of Barry Greene to its board of directors. Mr. Greene has more than 20 years of experience in the...


Jun 17, 2013, 08:00 ET Ambrx And Zhejiang Medicine Co. Ltd. Form Collaboration To Develop And Commercialize Ambrx's Antibody Drug Conjugate For Breast Cancer

 Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's...


Apr 04, 2013, 21:00 ET Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology

 Astellas Pharma Inc. (Tokyo: 4503, "Astellas") today entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development...


Jun 18, 2012, 05:30 ET Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates

 Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug...


Jun 22, 2011, 08:00 ET Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences

Ambrx Inc. today announced that Ho Cho, Ph.D., the company's Chief Technology Officer, will present preclinical data from the company's antibody...


May 25, 2011, 08:00 ET Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology

Ambrx Inc. today announced that data from a Phase 1/2 study, published online ahead of print on May 16 by Proceedings of the National Academy of...


Feb 24, 2009, 09:00 ET Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance

Ambrx Inc, and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a global strategic collaboration to develop and...


Nov 13, 2008, 08:00 ET Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated

Long-Acting hGH Analogue Requires Only Weekly Dosing Ambrx Inc. today announced Phase I/II clinical trial data demonstrating that ARX201, the...


Nov 05, 2008, 08:00 ET Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue

Ambrx Inc. today announced the scheduled presentation of data from a Phase I/II clinical trial of ARX201, the company's long-acting human growth...


Dec 18, 2007, 00:00 ET Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.

SAN DIEGO, Dec. 18 /PRNewswire/ -- Ambrx Inc. today announced that it has entered into a global, strategic collaboration with Merck & Co....


Dec 17, 2007, 00:00 ET Ambrx Announces Drug Discovery Alliance With Eli Lilly and Company

SAN DIEGO, Dec. 17 /PRNewswire/ -- Privately held Ambrx Inc. today announced that it has entered into a collaboration with Eli Lilly and Company...


Jul 24, 2007, 01:00 ET Ambrx Appoints Stephen Kaldor Chief Executive Officer

SAN DIEGO, July 24 /PRNewswire/ -- Ambrx, Inc., today announced the appointment of Stephen Kaldor, Ph.D., as President and Chief Executive...


Jul 24, 2006, 01:00 ET Ambrx Secures Additional $3 Million in Series C Financing

SAN DIEGO, July 24 /PRNewswire/ -- Ambrx, Inc., announced today it has secured commitments for an additional $3 million in Series C financing....


Jul 05, 2006, 01:00 ET Ambrx Secures $52 Million in Series C Financing

SAN DIEGO, July 5 /PRNewswire/ -- Ambrx, Inc., announced today it has secured commitments for $52 million in Series C financing from a broad,...


Jan 10, 2006, 00:00 ET Ambrx to Present at the 24th Annual JPMorgan Healthcare Conference

LA JOLLA, Calif., Jan. 10 /PRNewswire/ -- Ambrx, Inc. today announced that Martin A. Mattingly, the Company's president and chief executive...


Dec 08, 2005, 00:00 ET Ambrx and Roche Enter Into Broad Technology Collaboration

BASEL, Switzerland and SAN DIEGO, Dec. 8 /PRNewswire/ -- Roche and Ambrx Inc. today announced a collaboration in which Ambrx will use its...


Sep 20, 2005, 01:00 ET Ambrx Appoints Martin A. Mattingly as President and CEO

SAN DIEGO, Sept. 20 /PRNewswire/ -- Ambrx, Inc., announced today the appointment of Martin A Mattingly, Pharm.D. as President and Chief...


Apr 13, 2005, 01:00 ET Ambrx Appoints Dr. August Watanabe to Board of Directors

SAN DIEGO, April 13 /PRNewswire/ -- Ambrx, Inc., today announced the appointment of August M. Watanabe, M.D. to its Board of Directors. Dr....


Apr 08, 2005, 01:00 ET Ambrx Completes $23.4 Million Private Placement

SAN DIEGO, April 8 /PRNewswire/ -- Ambrx, Inc., today announced the completion of a $23.4 million preferred stock financing. The funds will be...


Apr 06, 2005, 01:00 ET Ambrx Appoints Bruce Kimmel, Ph.D. as Vice President, Therapeutic Applications

SAN DIEGO, April 6 /PRNewswire/ -- Ambrx, Inc., announced today the appointment of Bruce Kimmel, Ph.D. as Vice President, Therapeutic...


Sep 22, 2003, 01:00 ET Ambrx Assembles World Class Team and Raises $12.5 Million to Apply Breakthrough Technology to Protein Therapeutics

SAN DIEGO, Sept. 22 /PRNewswire/ -- Ambrx, Inc., a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics,...